November 21, 2018

What Does A Split Congress Mean For Drug Pricing Agenda?

Miranda A. Franco

In an article for Law360, Senior Policy Advisor Miranda Franco and Public Affairs Advisor Ethan Jorgensen-Earp analyze the effects of a split Congress on drug pricing. Drug pricing will be a significant focus of the 116th Congress and was a pillar of the Democratic party's healthcare agenda in the 2018 midterm elections. Now that they have won the majority in the House of Representatives, the Democrats will have to grapple with which proposals to advance and if they should try to temper the Trump Administration's aggressive pursuit of reform of the Affordable Care Act.

Most significantly, they will also have to decide whether they will work with the Republican Party and Senate. Although both sides of the aisle agree that drug prices need to be reduced, the major political differences between the two parties and chambers have the potential to generate roadblocks, according to the authors. So it remains unclear if partnership on drug prices is realistic or if it will be stalemated as it has been in the past.

READ: What Does A Split Congress Mean For Drug Pricing Agenda? (Subscription required)

Related Insights